{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:36:19Z","timestamp":1789011379107,"version":"build-2803163510"},"reference-count":27,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although chemoimmunotherapy is the current standard of care for initial treatment of mantle cell lymphoma (MCL), newer data suggest that there may be a role for a chemotherapy-free approach. We report the 9-year follow-up results of a multicenter, phase 2 study of lenalidomide plus rituximab (LR) as the initial treatment of MCL. The LR doublet is used as induction and maintenance until progression, with optional discontinuation after 3 years. We previously reported an overall response rate of 92% in evaluable patients, with 64% achieving a complete response. At a median follow-up of 103\u00a0months, 17 of 36 evaluable patients (47%) remain in remission. The 9-year progression-free survival and overall survival were 51% and 66%, respectively. During maintenance, hematologic adverse events included asymptomatic grade 3 or 4 cytopenia (42% neutropenia, 5% thrombocytopenia, and 3% anemia) and mostly grade 1 to 2 infections managed in the outpatient setting (50% upper respiratory infections, 21% urinary tract infections, 16% sinusitis, 16% cellulitis, and 13% pneumonia, with 5% requiring hospitalization). More patients developed grade 1 and 2 neuropathy during maintenance therapy (29%) than during induction therapy (8%). Twenty-one percent of patients developed secondary malignancies, including 5% with invasive malignancies, whereas the remainder were noninvasive skin cancers treated with local skin-directed therapy. Two patients permanently discontinued therapy because of concerns of immunosuppression during the COVID-19 pandemic. With long-term follow-up, LR continues to demonstrate prolonged, durable responses with manageable safety as initial induction therapy. This trial was registered at www.clinicaltrials.gov as #NCT01472562.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010606","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T13:13:45Z","timestamp":1694178825000},"page":"6579-6588","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma"],"prefix":"10.1182","volume":"7","author":[{"given":"Samuel","family":"Yamshon","sequence":"first","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui Zhen","family":"Chen","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Gribbin","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Christos","sequence":"additional","affiliation":[{"name":"2Division of Biostatistics and Epidemiology, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijal","family":"Shah","sequence":"additional","affiliation":[{"name":"3Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3376-8978","authenticated-orcid":false,"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[{"name":"4University of Pennsylvania Abramson Cancer Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9893-4949","authenticated-orcid":false,"given":"Sonali M.","family":"Smith","sequence":"additional","affiliation":[{"name":"5University of Chicago Medical Center, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[{"name":"4University of Pennsylvania Abramson Cancer Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R.","family":"Furman","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Ruan","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"issue":"1","key":"2023111415004206500_bib1","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era","volume":"117","author":"P\u00e9rez-Gal\u00e1n","year":"2011","journal-title":"Blood"},{"issue":"28","key":"2023111415004206500_bib2","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"2023111415004206500_bib3","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo\u2013purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2023111415004206500_bib4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2023111415004206500_bib5","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","article-title":"Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study","volume":"124","author":"Abrahamsson","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2023111415004206500_bib6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","article-title":"Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in\u00a0vivo","volume":"140","author":"Reddy","year":"2008","journal-title":"Br J Haematol"},{"issue":"24","key":"2023111415004206500_bib7","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.1158\/0008-5472.CAN-13-0750","article-title":"Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma","volume":"73","author":"Song","year":"2013","journal-title":"Cancer Res"},{"issue":"2","key":"2023111415004206500_bib8","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1158\/1078-0432.CCR-13-1569","article-title":"Antitumoral activity of lenalidomide in in\u00a0vitro and in\u00a0vivo models of mantle cell lymphoma involves the destabilization of cyclin D1\/p27KIP1 complexes","volume":"20","author":"Moros","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2023111415004206500_bib9","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21468","article-title":"Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in\u00a0vitro and in\u00a0vivo","volume":"84","author":"Zhang","year":"2009","journal-title":"Am J Hematol"},{"issue":"8","key":"2023111415004206500_bib10","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-14-2221","article-title":"Combination of lenalidomide and rituximab overcomes rituximab resistance in patients with indolent B-cell and mantle cell lymphomas","volume":"21","author":"Chong","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"29","key":"2023111415004206500_bib11","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"2023111415004206500_bib12","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood.V124.21.626.626","article-title":"Phase II randomized, multicenter study of lenalidomide vs best investigator\u2019s choice in relapsed\/refractory mantle cell lymphoma: results of the MCL-002 (SPRINT) study","volume":"124","author":"Trneny","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2023111415004206500_bib13","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"issue":"19","key":"2023111415004206500_bib14","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"2023111415004206500_bib15","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1182\/blood-2018-07-859769","article-title":"Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma","volume":"132","author":"Ruan","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2023111415004206500_bib16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.21.01797","article-title":"Ibrutinib with rituximab in first-line treatment of older patients with mantle cell lymphoma","volume":"40","author":"Jain","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2023111415004206500_bib17","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1200\/JCO.21.02321","article-title":"Ibrutinib in combination with rituximab for indolent clinical forms of mantle cell lymphoma (IMCL-2015): a multicenter, open-label, single-arm, phase II trial","volume":"40","author":"Gin\u00e9","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 1","key":"2023111415004206500_bib18","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2019-125681","article-title":"Ibrutinib, venetoclax plus obinutuzumab in newly diagnosed mantle cell lymphoma patients","volume":"134","author":"Le Gouill","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2023111415004206500_bib19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"9873","key":"2023111415004206500_bib20","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"12","key":"2023111415004206500_bib21","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"2023111415004206500_bib22","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","article-title":"Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study","volume":"19","author":"Robak","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"2023111415004206500_bib23","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of older patients with mantle cell lymphoma (MCL): long-term follow-up of the randomized European MCL Elderly trial","volume":"38","author":"Kluin-Nelemans","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"S2","key":"2023111415004206500_bib24","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/hon.2440_3","article-title":"MCL-R2 elderly: a phase III study of the European MCL Network assessing efficacy of alternating immunochemotherapy (R-CHOP \/ R-HAD) and a rituximab-lenalidomide maintenance","volume":"35","author":"Ribrag","year":"2017","journal-title":"Hematol Oncol"},{"issue":"suppl 1","key":"2023111415004206500_bib25","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood-2019-129323","article-title":"Minimal residual disease (MRD) assessment in the ECOG1411 randomized phase 2 trial of front-line bendamustine-rituximab (BR)-based induction followed by rituximab (R)\u00a0\u00b1 lenalidomide (L) consolidation for mantle cell lymphoma (MCL)","volume":"134","author":"Smith","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2023111415004206500_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1182\/blood-2022-158656","article-title":"Phase 2 trial of acalabrutinib-lenalidomide-rituximab (ALR) with real-time monitoring of MRD in patients with treatment-na\u00efve mantle cell lymphoma","volume":"140","author":"Ruan","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2023111415004206500_bib27","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2021-151831","article-title":"Preliminary safety and efficacy from a multicenter, investigator-initiated phase II study in untreated TP53 mutant mantle cell lymphoma with zanubrutinib, obinutuzumab, and venetoclax (BOVen)","volume":"138","author":"Kumar","year":"2021","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/21\/6579\/2089187\/blooda_adv-2023-010606-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/21\/6579\/2089187\/blooda_adv-2023-010606-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T10:07:23Z","timestamp":1699956443000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/21\/6579\/497771\/Nine-year-follow-up-of-lenalidomide-plus-rituximab"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":27,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2023,11,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010606","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]}}}